Acquisition Synergy Quartesian is now part of Veranex, aligning clinical data services with broader product design, regulatory, and market access capabilities. This presents an opportunity to upsell integrated solutions that cover from data management and statistics through to regulatory submissions and commercialization, emphasizing end-to-end support for biopharma and device clients.

Clinical Data Strength With over a decade of experience in statistical programming, data management, study design, and submission support, Quartesian has built credibility in delivering quality, speed, and control over trial data. This can be leveraged to target sponsors seeking reliable CRO partners for complex clinical data services and faster trial timelines.

Strategic Partnerships Historical collaborations with Medrio and Amyndas Pharmaceuticals signal a track record of partnering with eClinical technology providers and biotech players. Use these relationships to position Veranex as a preferred integrator for technology-enabled trials and for expanding services across partners' ecosystems.

Growth Profile Revenue range indicates a mid-market CRO with room for scale alongside larger players. Target mid to late-stage biopharma and medical device companies seeking agile, cost-effective data management and statistical services, while offering cross-sell opportunities into Veranex’s larger capabilities.

Geographic & Sector Fit Industry focus on pharmaceutical manufacturing and clinical data services, combined with Veranex’s broader design and regulatory expertise, creates a compelling case for clients pursuing end-to-end product development and lifecycle management. Propose bundled engagements spanning data management, statistics, device evaluation, and market access to capture integrated projects.